BACKGROUND: Prostate cancer patients diagnosed with low-and intermediate-risk disease have several treatment options. Decisional regret after treatment is a concern, especially when poor oncologic outcomes or declines in health-related quality of life (HRQoL) occur. This study assessed determinants of longitudinal decisional regret in prostate cancer patients attending a multidisciplinary clinic and treated with radical prostatectomy (RP), external beam radiation therapy (EBRT), brachytherapy (BT), or active surveillance (AS). METHODS: Patients newly diagnosed with prostate cancer at the Walter Reed National Military Medical Center who attended a multidisciplinary clinic were enrolled into a prospective study from 2006 to 2014. The Decision Regret Scale was administered at 6, 12, 24, and 36 months posttreatment. HRQoL was also assessed at regular intervals using the Expanded Prostate Cancer Index Composite and 36-item RAND Medical Outcomes Study Short Form questionnaires. Adjusted probabilities of reporting regret were estimated via multivariable logistic regression fitted with generalized estimating equations. RESULTS: A total of 652 patients met the inclusion criteria (395 RP, 141 EBRT, 41 BT, 75 AS). Decisional regret was consistently low after all of these treatments. In multivariable models, only African American race (odds ratio, 1.67; 95% confidence interval, 1.12-2.47) was associated with greater regret across time. Age and control preference were marginally associated with regret. Regret scores were similar between RP patients who did and did not experience biochemical recurrence. Declines in HRQoL were weakly correlated with greater decisional regret. CONCLUSION: In the context of a multidisciplinary clinic, decisional regret did not differ significantly between treatment groups but was greater in African Americans and those reporting poorer HRQoL. Cancer 2017;123:4252-8.
INTRODUCTION
Men diagnosed with low-and intermediate-risk prostate cancer are faced with the difficult task of selecting a course of treatment. Options include surgery, external beam radiation therapy, and brachytherapy, as well as disease management via active surveillance. While survival rates are high for all of these options, the potential complications and quality of life decrements associated with each can vary greatly. Declines in quality of life, or poor oncologic outcomes despite the favorable prognosis, can lead men to experience regret pertaining to their initial treatment choice.
Decisional regret is defined as "remorse or distress over a [treatment] decision." 1 Previous studies have found decisional regret to be common among prostate cancer patients, with 11%-18% of patients reporting that they regret their treatment choice. [2] [3] [4] [5] Regret has been associated with treatment toxicities, time since treatment, and patient demographics, including age, race, and educational attainment. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Regret may also differ by primary treatment modality, 11 though most studies have observed few or no discernible differences across treatment type. [3] [4] [5] 15 Understanding the determinants of regret may reveal strategies for mitigating it and improving patient quality of life.
One potential strategy for reducing regret following prostate cancer treatment involves the use of multidisciplinary prostate cancer clinics. 16, 17 At multidisciplinary clinics, patients meet with a series of specialists to discuss the benefits and harms of each treatment. These clinics are intended to provide balanced, individualized counseling and to facilitate shared decision-making. They may help to reduce posttreatment regret by ensuring that patients have sufficient information on each treatment as well as reasonable expectations. Despite the increasing use of multidisciplinary clinics, 18, 19 decisional regret of prostate cancer patients attending these clinics has not yet been assessed.
The goal of this study was to examine 3-year patterns in decisional regret of low-and intermediate-risk prostate cancer patients who attended a multidisciplinary clinic. Specifically, this study aimed to compare longitudinal regret across prostate cancer treatment groups, to examine associations between baseline factors and regret, and to examine associations between oncologic and health-related quality of life (HRQoL) outcomes and regret.
PATIENTS AND METHODS

Study Population
Beginning in June 2006, patients diagnosed with nonmetastatic prostate cancer at the Walter Reed National Military Medical Center (WRNMMC) were offered enrollment into a prospective study of prostate cancer treatment decision-making. The study was led by the WRNMMC site of the Center for Prostate Disease Research. The majority of patients enrolled in the decision-making study also participated in a concurrent HRQoL study. The design of these studies has been described previously. 20, 21 Both studies received institutional review board approval at WRNMMC, and all patients provided informed consent to participate. In accordance with the standard of care at WRNMMC, all patients enrolled in this study attended a multidisciplinary clinic to receive individualized counseling on their treatment options. The multidisciplinary clinic allowed patients and their spouse or significant other to meet with a urologic oncologist, radiation oncologist, andrologist, clinical psychologist or social worker, and nurse educator. 22 For this analysis, the study population was restricted to patients diagnosed with low-or intermediate-risk prostate cancer as defined by National Comprehensive Cancer Network (NCCN) criteria (clinical stage T2c, Gleason score 7, and diagnostic prostate-specific antigen [PSA] 20 ng/mL) between June 2006 and January 2014. Patients with high-risk prostate cancer were excluded, as these patients have a different constellation of treatment options and concerns influencing decisional regret. The study population was further restricted to patients choosing one of four primary treatment modalities of interest: radical prostatectomy (RP), external beam radiation therapy (EBRT), low-dose rate brachytherapy (BT), or active surveillance (AS). Patients receiving neoadjuvant hormone therapy in addition to EBRT were considered a distinct treatment group and were excluded. Patients were classified based on initial treatment choice; those selecting AS who later received definitive treatment were considered AS patients in this analysis.
Data Collection
Demographic information was collected at study enrollment using a preclinic survey, as described previously. 20 Clinical information was abstracted from patient medical records. Treatment information was obtained using follow-up surveys and confirmed using medical records.
Decisional regret was assessed using the Decision Regret Scale (DRS) at 6, 12, 24, and 36 months after the end of primary treatment. The DRS is a 5-item instrument that has been validated in prostate cancer patient populations. 1 The resulting score ranges from 0 to 100, with higher scores indicating greater decisional regret. The "end of treatment" for this study was determined to be the day of surgery or the last day of external beam radiation therapy or brachytherapy. The day patients provided notification of their decision to choose active surveillance was determined to be the "end of treatment" for active surveillance patients.
For patients dually enrolled in the quality of life study, HRQoL was assessed using 2 validated questionnaires: 1) the Expanded Prostate Cancer Index Composite, a prostate cancer-specific instrument; and 2) the 36-item RAND Medical Outcomes Study Short Form survey, a general health assessment instrument. [23] [24] [25] These questionnaires were administered at baseline (before treatment), at 3, 6, 9, 12, 18, 24, 30, and 36 months, and then annually for up to 10 years.
Statistical Analysis
Baseline demographic and clinical characteristics were compared across treatment groups using analysis of variance and chi-square tests. Patterns in missing data were explored by comparing regret scores for patients who did and did not complete the DRS at the subsequent time point. The distributions of continuous regret scores by treatment group and time point were graphed using box plots. Regret was also examined as a dichotomous outcome, with regret scores >25 considered indicative of regret. Using this binary variable, the odds of reporting regret were modeled using logistic regression fitted with generalized estimating equations, assuming an autoregressive correlation structure and using robust variance estimation. The base model included treatment group, time (treated categorically), time by treatment interactions, age at diagnosis (years), race (African American, non-African American), and NCCN risk stratum (low, intermediate).
An expanded model also adjusted for the presence of a major comorbidity, educational attainment, and preferred role in treatment decision-making (active, shared, passive). Models allowing for additional interaction between race and age (treated both continuously and categorically as <65 vs 65 years old) were also fit. For patients treated with RP, regret was compared between patients who did and did not experience a biochemical recurrence by 36 months using Wilcoxon rank sum and chi-square tests. For the RP and EBRT groups, correlation between the continuous regret score and change in HRQoL from baseline to 36 months (36 month score minus the baseline score) was assessed using Spearman rank correlation coefficients. Analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
As of January 31, 2014, there were 925 men enrolled in the decision-making study, including 782 who completed the DRS at 1 or more time points. Of these, 699 were diagnosed with NCCN low-or intermediate-risk prostate cancer, and 652 were treated with primary RP (n 5 395), EBRT (n 5 141), BT (n 5 41), or AS (n 5 75) (see Supporting Table 1 for additional details on these treatments). The baseline demographic and clinical characteristics of these 652 patients are provided in Table  1 . Of note, age at diagnosis, PSA at diagnosis, clinical Gleason sum, NCCN risk stratum, comorbidity status, and race/ethnicity varied significantly across the four treatment groups (Table 1) .
At each time point, approximately 60%-70% of patients within each treatment group completed the DRS Abbreviations: AS, active surveillance; BT, brachytherapy; EBRT, external beam radiation therapy; RP, radical prostatectomy. Data are presented as n (%).
( Table 2) . Regret scores at one time point were not associated with the likelihood of completing the DRS at the following time point (Supporting Table 2 ).
Comparison of Regret Across Treatment Groups
Decisional regret, as assessed by the DRS, was generally low following all four primary treatment options. The distribution of regret scores was extremely right-skewed, with the majority of patients reporting scores at or around zero (Fig. 1) . Median regret scores are provided in Supporting Table 3 . The percentage of patients reporting regret (defined as a DRS score >25) ranged from 6% to 25% depending on the treatment group and time point (Supporting Table 3 ). The percentage of patients reporting regret increased over time in the RP and EBRT groups, decreased over time in the AS group, and increased then decreased in the BT group. After adjusting for baseline differences across treatment groups in age, race/ethnicity, and NCCN risk stratum, the predicted probability of reporting regret scores >25 was highest in the RP and AS groups at 6 months, and highest in the EBRT group at all other time points (Fig. 2 , Supporting Table 4 ). However, differences between treatment groups were not statistically significant.
Baseline Factors Associated With Regret
According to the full multivariable model ( Probabilities of reporting regret. The probability of reporting regret (defined as a DRS score >25) ranged from 7% to 26% depending on the treatment group and time point, after adjusting for age, race/ethnicity, and NCCN risk stratum. Regret was highest in the external beam radiation therapy (EBRT) group and increased over time in the EBRT and radical prostatectomy groups. Differences in regret across treatment group were not statistically significant. with regret (P 5 .05). Compared with men who preferred to play an active role in treatment decision-making, those preferring a shared role were more likely to report regret (OR, 1.37; 95% CI, 0.89-2.10), whereas those preferring a passive role were less likely to report regret (OR, 0.39; 95% CI, 0.11-1.42). There was no association between regret and NCCN risk stratum, presence of a major comorbidity, or education attainment within this study population. No interaction between age and race was observed, both when age was treated continuously (P-interaction 5 .57) and categorically (P-interaction 5 .36).
Oncologic and HRQoL Outcomes and Regret
Of the 382 patients treated with RP who had follow-up PSA information available, 22 (5.8%) experienced a biochemical recurrence (BCR) within 36 months. Regret scores were similar among patients who did and did not experience BCR (median DRS score was 5 for patients without BCR and 7.5 for patients with BCR). At 36 months, 19% of patients without BCR and 25% with BCR reported regret scores >25 (P 5 .51). Changes in HRQoL from baseline to 36 months were weakly correlated with decisional regret. Within the RP group, patients who reported greater losses in sexual function, sexual bother, and bowel bother tended to report greater regret. In the EBRT group, change in sexual bother was negatively correlated with regret, whereas change in urinary function and bother also appeared weakly correlated (Table 4) .
DISCUSSION
Overall, this prospective study found decisional regret to be low for 3 years following treatment or surveillance of low-and intermediate-risk prostate cancer. There were no striking differences in regret across treatment groups or between patients who did and did not experience a biochemical recurrence after surgery. There were, however, differences in regret by race and suggestive evidence of a relationship between regret and HRQoL.
In this study, the prevalence of decisional regret was similar to that of previously published reports. [2] [3] [4] [5] [6] 8, 12 We hypothesized that decisional regret might be lower among patients attending a multidisciplinary clinic, because a previous study found lower regret among patients whose care included "discussion of all treatment options." 26 Direct comparison between this study and others is limited, however, as both the instruments for assessing regret as well as the interpretation of the instruments vary greatly across studies.
In this study, African Americans had a 1.67 times greater odds of reporting regret than whites and other racial/ethnic groups, after adjustment for age, NCCN risk stratum, comorbidity, educational attainment, and control preference. This finding is consistent with previous studies that observed an almost 2-fold difference in decisional regret between African Americans and whites who underwent robotic-assisted laparoscopic prostatectomy 8 or had biochemically recurrent prostate cancer. 27 A third study found no difference in decisional regret across race for prostate cancer patients younger than 65, but greater regret among whites compared with African Americans in patients 65 years of age.
3 The current study also tested for an interaction between age and race, but no interaction was observed. It is unclear why African Americans in this cohort were more likely to report decisional regret, but racial differences in regret may be closely tied to racial differences in self-reported HRQoL, and future studies exploring the interplay between race, decisional regret, and HRQoL are warranted.
Our study has several key strengths. The first is that all patients attended a multidisciplinary prostate cancer clinic. These clinics are becoming increasingly common, 18, 19 and our results may be particularly pertinent to patients receiving care at these clinics. The multidisciplinary clinic setting is also a methodological strength, because all patients in this study received similar counseling on their treatment options from the same set of specialists. Thus, any observed differences in regret were unlikely to be confounded by differential access to care or patient knowledge.
Second, decisional regret was assessed at several follow-up time points, allowing for examination of temporal trends over a 3-year period. Most other studies have measured regret at a single time point, despite the fact that decisional regret is not static but may change over time. Longitudinal trends in regret may be particularly informative for patients aiming to choose a treatment modality that minimizes regret both immediately and in the long term. Our study found that regret increased over time in RP and EBRT patients, possibly due to frustration over lingering quality of life decrements. In contrast, regret decreased over time among AS patients and at 36 months for BT patients, suggesting that these patient groups may have become more comfortable with their initial treatment decisions over time.
Additional study strengths include the prospective study design, the racial diversity of the cohort, and the use of the DRS. Other studies have used several different scales to assess decisional regret, but the DRS is the most common and the only scale that has been validated. 17 Use of the DRS may thus facilitate comparisons between this study and others. 17 Our study results must be generalized with caution, because the study was conducted at a single US military institution. There are also inherent limitations of the DRS, including the lack of standard cut-points to define high and low levels of regret. 17 Not all patients completed the DRS at each follow-up, raising concerns of biases due to missing data, but there did not appear to be differences in regret between patients who completed the DRS at the subsequent time point and those who did not (Supporting Table 2 ). Finally, this study cannot directly assess the impact of multidisciplinary counseling on decisional regret, as there was no comparison group of patients treated in a non-multidisciplinary setting. Despite these limitations, our study provides evidence that decisional regret among patients receiving care at these clinics remains low for the majority of patients for a 3-year period. These study results may prove comforting to patients who are in the process of making treatment decisions for low-and intermediate-risk prostate cancer.
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